// App-Quantinova.ai

P48.17 : Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib

Researchers

Presenter

  • J. Nieva

Principal Investigators

  • A. Taylor

  • P. Sun

  • R. Mathur

Medical Centers

  • 4Astrazeneca, Cambridge/GB

  • Flatiron, New York/NY/US

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Astrazeneca, Gaithersburg/US

  • Astrazeneca, Gaithersburg/US

  • Iqvia, London/GB

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Tagrisso

Outcome

  • N/A

Study Design

  • Multicenteric

  • Prospective

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved